Sunburn
Drug research and approvals for sunburn: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 0 studies of sunburn are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 0
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Drug Pipeline
12 approved, 2 in phase 3, 4 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Titanium dioxide, Lidocaine, Zinc oxide, Diphenhydramine, Dibucaine, Menthol, Pramoxine, Benzocaine, Dimethicone, Salicylic acid, Octinoxate, Avobenzone
- Dexchlorpheniramine
- Phase 3 Histamine H1 receptor antagonist
- Diclofenac
- Phase 3 Cyclooxygenase inhibitor
- Ibuprofen
- Phase 2 Cyclooxygenase inhibitor
- Chlorpheniramine
- Phase 2 Histamine H1 receptor antagonist
- Petrolatum
- Phase 2
- Bemotrizinol
- Phase 2
- Melatonin
- Phase 1 Melatonin receptor agonist
How Its Trials Ended
23 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong- Completed, result not reported1252%
- Status unknown522%
- Ongoing313%
- Met its primary endpoint14%
- Stopped: sponsor or business decision14%
- Stopped: other or unclear14%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA